KIMS Share Price in Focus; Receives Listing Approval for 1,98,67,549 Equity Shares from BSE and NSE

Krishna Institute of Medical Sciences (KIMS) has obtained listing approval from both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) for 1,98,67,549 equity shares of ₹2 each. These shares were issued to qualified institutional buyers through a qualified institutional placement. 

Details of the Listing Approval 

The listing approval pertains to the equity shares bearing distinctive numbers from 4,00,13,893 to 4,20,00,648. The approval was granted following the company's application dated June 22, 2026. This approval allows the shares to be dealt in on the respective exchanges. 

Conditions for Trading 

Trading of these shares will commence once the company files the necessary documents with the exchanges. This includes obtaining listing approval from NSE and confirmation letters from CDSL and NSDL regarding the crediting of shares to beneficiaries' accounts. 

Read More: India Aims to Double UK Textile Market Share with Zero-Tariff FTA! 

Approval from NSE 

The NSE has also granted in-principle approval for the listing of these equity shares. The shares will be listed and admitted to dealings on the exchange upon receipt of confirmation from NSDL and CDSL regarding the credit of beneficiaries' accounts. 

Krishna Institute of Medical Sciences Share Price Performance  

As of June 23, 2026, at 3:30 PM, Krishna Institute of Medical Sciences share price on NSE was closed at ₹807.35, up by 0.15% from the previous closing price. 

Conclusion 

Krishna Institute of Medical Sciences has received approval from BSE and NSE for the listing of 1,98,67,549 equity shares of ₹2 each. The shares, issued through a qualified institutional placement, are set to be traded upon fulfilling specific conditions. 

Read stock market news in Hindi. Head to Angel One's share market news in Hindi for comprehensive coverage. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.